[1]杨菊红,孔岩,张立弋,等.口服降糖药物对2型糖尿病患者心血管结局的影响[J].国际内分泌代谢杂志,2017,37(05):324-328.
　Yang Juhong,Kong Yan,Zhang Liyi,et al.Effects of hypoglycemic agents on cardiovascular outcome[J].International Journal of Endocrinology and Metabolism,2017,37(05):324-328.
点击复制

口服降糖药物对2型糖尿病患者心血管结局的影响()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
37
期数:
2017年05期
页码:
324-328
栏目:
综述
出版日期:
2017-09-20

文章信息/Info

Title:
Effects of hypoglycemic agents on cardiovascular outcome
作者:
杨菊红; 孔岩; 张立弋; 单春艳
300070 天津医科大学代谢病医院糖尿病肾病科,天津医科大学代谢病医院内分泌研究所,卫生部激素与发育重点实验室,天津市代谢性疾病重点实验室
Author(s):
Yang Juhong;  Kong Yan;  Zhang Liyi;  Shan Chunyan.
Department of Diabetic Nephropathy, Key Laboratory of Hormones and Development(Ministry of Health), Tianjin Key Laboratory of Metabolic Diseases, The Metabolic Diseases Hospital & Tianjin Institute of Endocrinology, Tianjin Medical University, Tianjin 300070, China
关键词:
糖尿病;  心血管疾病;  心力衰竭;  降糖药物
Keywords:
Diabetes mellitus;  Cardiovascular diseases;  Heart failure;  Hypoglycemic agents
文献标志码:
A
摘要:
改善血糖控制可减少糖尿病患者的心血管并发症,不同药物的作用机制不同,其对心血管结局的影响不同。此外,继2007年对罗格列酮潜在心血管风险的认识之后,陆续开展了大量的前瞻性、随机、对照研究,评估降糖药物对糖尿病患者的心血管系统的影响。传统药物中二甲双胍及噻唑烷二酮类药物对糖尿病患者的心血管系统具有保护作用,但必须警惕噻唑烷二酮类药物可增加心力衰竭的风险; 第二代及第三代磺脲类促泌剂及非磺脲类促泌剂并不增加患者心血管事件的发生风险。新型药物中并没有看到二肽基肽酶4抑制剂对心血管系统具有有利或不良影响,是否增加心力衰竭风险目前结果并不统一。而胰高血糖糖素样肽-1受体激动剂及钠-葡萄糖协同转运蛋白2可减少糖尿病患者的心血管疾病风险并降低死亡率; 但由于数据有限,仍需要更广泛的研究加以证实。
Abstract:
Beneficial effect of improved glycemic control on cardiovascular complications has been well established. However, different hypoglycemic agents have different effects on cardiovascular outcome because of their different pharmaceutical function. Since 2007, the rosiglitazone experience aroused awareness of potential cardiovascular risk associated with diabetes drugs. Large prospective randomized clinical researches exploring the cardiovascular safety of hypoglycemic agents have been designed and finished. Among the traditional agents, metformin and thiazolidinedione are associated with improved cardiovascular outcome, although there is an increased risk of heart failure for thiazolidinedione. Insulin secretagogues including the second and the third generention of sulfonylurea insulin secretagogues and non-sulfonylurea insulin secretagogues are neutral in respect of their cardiovascular risks. Among the new agents, dipeptidyl peptidase 4 inhibitor does not increase or decrease cardiovascular event and the evidence in term of their risk of heart failure are inconsistent. Glucagon-like peptide-1 receptor agonist and sodium/glucose cotransporter 2 are proved to decrease the risk of cardiovascular disease as well as the mortality in type 2 diabetic patients. However, because the evidence is limited, further researches are still needed to draw the final conclusion.

参考文献/References:

[1] Maruthur NM, Tseng E, Hutfless S,et al. Diabetes medications as monotherapy or metformin-based combination therapy for type 2 diabetes: a systematic review and meta-analysis[J].Ann Intern Med,2016,164(11):740-751. DOI:10.7326/M15-2650.
[2] Preiss D, Lloyd SM, Ford I,et al. Metformin for non-diabetic patients with coronary heart disease(the CAMERA study): a randomised controlled trial[J].Lancet Diabetes Endocrinol,2014,2(2):116-124. DOI:10.1016/S2213-8587(13)70152-9.
[3] El Messaoudi S, Nederlof R, Zuurbier CJ,et al. Effect of metformin pretreatment on myocardial injury during coronary artery bypass surgery in patients without diabetes(MetCAB): a double-blind, randomised controlled trial[J].Lancet Diabetes Endocrinol, 2015,3(8):615-623. DOI:10.1016/S2213-8587(15)00121-7.
[4] Varvaki Rados D, Catani Pinto L, Reck Remonti L,et al. The association between sulfonylurea use and all-cause and cardiovascular mortality: a meta-analysis with trial sequential analysis of randomized clinical trials[J].PLoS Med,2016,13(4):e1001992. DOI:10.1371/journal.pmed.1001992.
[5] Schramm TK, Gislason GH, Vaag A,et al. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study[J].Eur Heart J,2011,32(15):1900-1908. DOI:10.1093/eurheartj/ehr077.
[6] Huang Y, Abdelmoneim AS, Light P,et al. Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study[J].J Diabetes Complications,2015,29(2):196-202. DOI:10.1016/j.jdiacomp.2014.11.012.
[7] Dormandy JA, Charbonnel B, Eckland DJ,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study(PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial[J].Lancet,2005,366(9493):1279-1289. DOI:10.1016/S0140-6736(05)67528-9.
[8] Kernan WN, Viscoli CM, Furie KL,et al.Pioglitazone after ischemic stroke or transient ischemic attack[J].N Engl J Med,2016,374(14):1321-1331. DOI:10.1056/NEJMoa1506930.
[9] Holman RR, Bethel MA, Chan JC, et al. Rationale for and design of the Acarbose Cardiovascular Evaluation(ACE)trial[J].Am Heart J,2014,168(1):23-29.e2. DOI:10.1016/j.ahj.2014.03.021.
[10] White WB, Cannon CP, Heller SR,et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes[J].N Engl J Med,2013,369(14):1327-1335. DOI:10.1056/NEJMoa1305889.
[11] Scirica BM, Bhatt DL, Braunwald E,et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus[J].N Engl J Med,2013,369(14):1317-1326. DOI:10.1056/NEJMoa1307684.
[12] Green JB, Bethel MA, Armstrong PW,et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2015,373(3):232-242. DOI:10.1056/NEJMoa1501352.
[13] Scirica BM, Braunwald E, Raz I,et al. Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial[J].Circulation,2014,130(18):1579-1588. DOI:10.1161/CIRCULATIONAHA.114.010389.
[14] Fonarow GC. Diabetes medications and heart failure: recognizing the risk[J].Circulation,2014,130(18):1565-1567.DOI:10.1161/CIRCULATIONAHA.114.012883.
[15] Bhatt DL, Cavender MA. Do dipeptidyl peptidase-4 inhibitors increase the risk of heart failure?[J].JACC Heart Fail,2014,2(6):583-585. DOI:10.1016/j.jchf.2014.05.005.
[16] Wu S, Hopper I, Skiba M,et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular outcomes: meta-analysis of randomized clinical trials with 55,141 participants[J].Cardiovasc Ther,2014,32(4):147-158. DOI:10.1111/1755-5922.12075.
[17] McGuire DK, Van de Werf F, Armstrong PW,et al. Association between sitagliptin use and heart failure hospitalization and related outcomes in type 2 diabetes mellitus: secondary analysis of a randomized clinical trial[J].JAMA Cardiol,2016,1(2):126-135. DOI:10.1001/jamacardio.2016.0103.
[18] Pfeffer MA, Claggett B, Diaz R,et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome[J].N Engl J Med,2015,373(23):2247-2257.DOI:10.1056/NEJMoa1509225.
[19] Marso SP, Daniels GH, Brown-Frandsen K,et al. Liraglutide and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2016,375(4):311-322. DOI:10.1056/NEJMoa1603827.
[20] Marso SP, Bain SC, Consoli A,et al. Semaglutide and ardiovascular outcomes in patients with type 2 diabetes[J].N Engl J Med,2016,375(19):1834-1844. DOI:10.1056/NEJMoa1607141.
[21] Zinman B, Wanner C, Lachin JM,et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes[J].N Engl J Med,2015,373(22):2117-2128. DOI:10.1056/NEJMoa1504720.
[22] Rajasekeran H, Lytvyn Y, Cherney DZ. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis[J].Kidney Int,2016,89(3):524-526. DOI:10.1016/j.kint.2015.12.038.
[23] DeFronzo RA. The EMPA-REG study: what has it told us a diabetologist's perspective[J].J Diabetes Complications,2016,30(1):1-2. DOI:10.1016/j.jdiacomp.2015.10.013.
[24] Ferrannini E, Mark M, Mayoux E. CV protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis[J].Diabetes Care,2016,39(7):1108-1114. DOI:10.2337/dc16-0330.
[25] Fioretto P, Mansfield TA, Ptaszynska A,et al. Long-term safety of dapagliflozin in older patients with type 2 diabetes mellitus: a pooled analysis of phase Ⅱb/Ⅲ studies[J].Drugs Aging,2016,33(7):511-522. DOI:10.1007/s40266-016-0382-1.
[26] Cefalu WT, Leiter LA, de Bruin TW,et al. Dapagliflozin's effects on glycemia and cardiovascular risk factors in high-risk patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled study with a 28-week extension[J].Diabetes Care,2015,38(7):1218-1227. DOI:10.2337/dc14-0315.
[27] Tang H, Fang Z, Wang T,et al. Meta-analysis of effects of sodium-glucose cotransporter 2 inhibitors on cardiovascular outcomes and all-cause mortality among patients with type 2 diabetes mellitus[J].Am J Cardiol,2016,118(11):1774-1780. DOI:10.1016/j.amjcard.2016.08.061.
[28] Davies MJ, Trujillo A, Vijapurkar U,et al. Effect of canagliflozin on serum uric acid in patients with type 2 diabetes mellitus[J].Diabetes Obes Metab,2015,17(4):426-429. DOI:0.1111/dom.12439.
[29] Dziuba J, Alperin P, Racketa J,et al. Modeling effects of SGLT-2 inhibitor dapagliflozin treatment versus standard diabetes therapy on cardiovascular and microvascular outcomes[J].Diabetes Obes Metab,2014,16(7):628-635. DOI:10.1111/dom.12261.
[30] Kosiborod M, Cavender MA, Fu AZ,et al. Lower risk of heart failure and death in patients initiated on SGLT-2 inhibitors versus other glucose-lowering drugs: the CVD-REAL study[J].Circulation,2017,136(3):249-259. DOI:10.1161/CIRCULATIONAHA.117.029190.

相似文献/References:

[1]郑少雄.罗格列酮和心血管风险——近期文献解读[J].国际内分泌代谢杂志,2007,(04):231.
[2]凌厉,朱本章.胰岛素类似物安全性研究进展[J].国际内分泌代谢杂志,2007,(04):234.
[3]李颖,刘东方.餐后1小时血糖升高的意义及干预[J].国际内分泌代谢杂志,2007,(04):235.
[4]崔巍,施秉银.内质网应激介导β细胞生存/死亡的研究进展[J].国际内分泌代谢杂志,2007,(04):256.
[5]杨叶虹,胡仁明.SELDI-TOF-MS技术及其在糖尿病研究中的应用[J].国际内分泌代谢杂志,2007,(04):261.
[6]高妍.针对华人糖尿病特点优化降糖方案[J].国际内分泌代谢杂志,2007,(04):269.
[7]杨志霞,郭莹辉,杨永生,等.胰岛素泵和多次皮下注射治疗糖尿病的比较[J].国际内分泌代谢杂志,2007,(04):273.
[8]周建英,马向华.胃旁路术减肥同时改善糖代谢的机制[J].国际内分泌代谢杂志,2007,(04):285.
[9]李翠柳,朱大龙.破译肠道代谢信息,驱动治疗革新[J].国际内分泌代谢杂志,2014,(06):383.[doi:10.3760/cma.j.issn.1673-4157.2014.06.006]
　Li Cuiliu*,Zhu Dalong..Deciphering metabolic messages from the gut drives therapeutic innovation[J].International Journal of Endocrinology and Metabolism,2014,(05):383.[doi:10.3760/cma.j.issn.1673-4157.2014.06.006]
[10]袁捷 姜云生 杜彦丽 王肃.1型糖尿病对小鼠早孕时期子宫肌层结构和细胞增殖的影响[J].国际内分泌代谢杂志,2015,(01):6.[doi:10.3760/cma.j.issn.1673-4157.2015.01.002]
　Yuan JieJiang YunshengDu YanliWang Su.Effects of type 1 diabetes on the muscularis structure and cell proliferation of uterine in mice during early pregnancy[J].International Journal of Endocrinology and Metabolism,2015,(05):6.[doi:10.3760/cma.j.issn.1673-4157.2015.01.002]
[11]王晓来.糖尿病相关血管钙化[J].国际内分泌代谢杂志,2015,(06):406.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.012]
　Wang Xiaolai.Diabetes-related vascular calcification[J].International Journal of Endocrinology and Metabolism,2015,(05):406.[doi:DOI:10.3760/cma.j.issn.1673-4157.2015.06.012]

备注/Memo

备注/Memo:
基金项目:国家自然科学基金资助项目(81473472); 天津市应用基础与前沿技术研究计划(17JCZDJC34700)
通信作者:单春艳,Email:chunyanshan@yahoo.com
更新日期/Last Update: 2017-09-30